China Biologic to Participate in Upcoming Investor Conferences
BEIJING, Aug. 29, 2013
BEIJING, Aug. 29, 2013 /PRNewswire-FirstCall/ --China Biologic Products, Inc.
(Nasdaq: CBPO, "China Biologic" or the "Company"), a leading fully integrated
plasma-based biopharmaceutical company in China, is scheduled to participate
in the upcoming conferences:
oCredit Suisse Asian Healthcare Conference, to be held September 3, 2013 at
the Credit Suisse office at International Commerce Centre, Hong Kong.
Management is scheduled to meet with institutional investors throughout
Tuesday, September 3.
oMorgan Stanley Global Healthcare Conference, to be held September 9-11,
2013 at the Grand Hyatt New York. Management is scheduled to meet with
institutional investors throughout the event.
For additional information, please contact the respective institutional sales
representative at each sponsoring bank.
About China Biologic Products, Inc.
China Biologic Products, Inc. (Nasdaq: CBPO), is a leading fully integrated
plasma-based biopharmaceutical company in China. The Company's products are
used as critical therapies during medical emergencies and for the prevention
and treatment of life-threatening diseases and immune-deficiency related
diseases. China Biologic is headquartered in Beijing and manufactures over 20
plasma-based products through its indirect majority-owned subsidiaries,
Shandong Taibang Biological Products Co., Ltd. and Guiyang Dalin Biologic
Technologies Co., Ltd. The Company also has an equity investment in Xi'an
Huitian Blood Products Co., Ltd. The Company sells its products to hospitals
and other healthcare facilities in China. For additional information, please
see the Company's website www.chinabiologic.com.
China Biologic Products, Inc.
Mr. Ming Yin
Mr. Bill Zima
Phone: +86-10-6583-7511 or +1-646-405-5191
SOURCE China Biologic Products, Inc.
Press spacebar to pause and continue. Press esc to stop.